ArticleJournal of inflammation research2025
Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine learning-guided multimodal profiling defines perturbed immune states at the time of cancer diagnosis.Briefings in bioinformatics · 2026Article
- Advances in Artificial Intelligence for Glioblastoma Radiotherapy Planning and Treatment.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Glioma is the most common primary brain tumor, with a specific immune microenvironment and aggressive nature. Novel systemic immune-inflammation indices (nSII) are the most comprehensive non-invasive biomarkers that represent patients' peripheral immune status, which are urgently needed to improve clinical management. However, the diagnostic and prognostic value of nSII in glioma remains unknown. Methods: From October 2006 to April 2022, 1282 patients with primary glioma were enrolled. The preoperative peripheral blood samples were collected. Correlations between novel systemic immune-inflammation indices (nSII) and glioma grades and subtypes were analyzed using ANOVA, Results: With the higher clinical grade, the percentage of NK cells increases while Th lymphocytes and T lymphocytes decrease. The percentage of NK and Th cells was also correlated with glioma subtypes. In glioblastoma patients, the higher percentage of immunoglobulin light chains was associated with a favorable prognosis, whereas the higher percentage of B lymphocytes was associated with a poor prognosis. Our study showed high diagnostic potential, eg, combined model (C4 & NK & B cells) AUC 0.879 (grade I vs IV), combined model (Th & NK & T cells) AUC 0.845 (grade II vs IV), and combined model (C4 & NK & T cells) AUC 0.711 (grade III vs IV). Conclusion: The nSII can serve as a robust non-invasive diagnostic and prognostic biomarker in glioma, thus promoting clinical management in screening, stratification, and treatment optimization. This study also provides a comprehensive perspective on glioma's systemic and intracranial immune landscape, paving the way for future translational applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.